Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 432-440

  Kaku, K ^a   Inoue, S ^b   Matsuoka, O ^c   Kiyosue, A ^d   Azuma, H ^e   Hayashi, N ^f   Tokudome, T ^g   Langkilde, A M ^h   Parikh, S ^f  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Medical Corporation Heishinkai OCROM Clinic   (Japan)

^c Medical Corporation Heishinkai ToCROM Clinic   (Japan)

^d Tokyo Eki Center Building Clinic   (Japan)

^e Yaesu Sakura dori Clinic   (Japan)

^f ASTRAZENECA   (United Kingdom)

^g R and D   (Japan)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

Clinical trial; Diabetes mellitus; Phase I II study; Randomized trial; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84876335563     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12047     Document Type: Article

References (22)

1. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812.
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
3. Blonde L. State of diabetes care in the United States. Am J Manag Care 2007; 13(Suppl. 2): S36-40.
4. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551-559.
5. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
6. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
7. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
8. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-2224.
9. Strojek K, Yoon KH, Hruba B, Elze M, Langkilde AMPS. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
10. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
11. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
12. Nauck MA, Del PS, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
13. Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with metformin alone. Diabetes 2011; 60(Suppl. 1): A271 [Abstract 988-P].
14. Henry R, Murray A, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM. Diabetes 2011; 60(Suppl. 1): A84. [Abstract 307-OR].
15. levey AS, Greene T, Kusek J, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.
16. Bailey CJ, Gross JL, Bastone L, Bastien A, List JF. Dapagliflozin as an add-on to metformin lowers hyperlgycaemia in type 2 diabetes patients inadequately controlled with metformin alone. Diabetologia 2009; 52(Suppl. 1): S76 [Abstract 169].
17. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
18. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
19. Kasichayanula S, Chang M, Hasegawa M et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 357-365.
20. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008; 64: 707-715.
21. Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med 2008; 27: 4658-4677.
22. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.